Mushtaque Chachar, MD
Neurology · New Bedford, MANPI 1891903712
Payments from drug & device makers
Across 341 payments — averaging $1605.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$176K
- American Regent$86K
- Daiichi Sankyo Inc.$80K
- Vertex$60K
- Biohaven Pharmaceutical Holding Company Ltd.$47K
- UCB SA$28K
- plus $70K from 32 others
Across 1 payment — averaging $2615.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 27 | $176,425 |
| American Regent | 9 | $86,011 |
| Daiichi Sankyo Inc. | 86 | $80,376 |
| Vertex | 3 | $59,838 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $47,389 |
| UCB SA | 1 | $27,655 |
| Alnylam Pharmaceuticals Inc. | 10 | $25,187 |
| AbbVie(2 entities) | 28 | $17,076 |
| Vanda Pharmaceuticals Inc. | 7 | $16,970 |
| Avanir Pharmaceuticals, Inc. | 1 | $3,000 |
| Livanova USA, Inc. | 2 | $2,885 |
| Pfizer | 35 | $2,437 |
| Sunovion Pharmaceuticals Inc. | 26 | $317 |
| Novartis | 20 | $288 |
| Teva Pharmaceuticals USA, Inc. | 13 | $274 |
| E.r. Squibb & Sons, L.L.C. | 4 | $229 |
| Biogen | 6 | $143 |
| Lilly USA, LLC | 6 | $116 |
| Sumitomo Pharma America, Inc. | 5 | $109 |
| Lundbeck LLC | 5 | $104 |
| Neurelis, Inc. | 5 | $97 |
| Jazz Pharmaceuticals Inc. | 5 | $97 |
| EMD Serono, Inc. | 4 | $69 |
| SK Life Science, Inc. | 2 | $65 |
| Cycle Pharmaceuticals Inc | 3 | $59 |
| Insightec,inc | 2 | $51 |
| Azurity Pharmaceuticals, Inc. | 2 | $48 |
| Supernus Pharmaceuticals, Inc. | 2 | $48 |
| Kyowa Kirin, Inc. | 2 | $36 |
| Argenx US, Inc. | 1 | $34 |
| Merck | 2 | $31 |
| Scilex Pharmaceuticals Inc. | 1 | $25 |
| Bristol Myers Squibb | 1 | $22 |
| Johnson & Johnson | 1 | $20 |
| Aucta Pharmaceuticals, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| UCB, Inc. | 1 | $15 |
How this compares
$547,596 in reported general payments places this provider in the 90th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in New Bedford
- Stephanie RutrickBoston$31.4M
- Scott PlotkinBoston$26.3M
- Patrick WenBoston$18.2M
- James BerryBoston$8.9M
- Isabel Arrillaga-RomanyBoston$8.2M
- Donald MarksPlymouth$7.8M
- Mahmut GurolBoston$7.4M
- Gad MarshallBoston$6M
- Shawn MurphyBoston$5.9M
- Suma BabuBoston$5.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.